Thomas Lynch, MD
Internal Medicine · Baltimore, MDNPI 1659312791
Payments from drug & device makers
Across 127 payments — averaging $14.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$262
- Novo Nordisk$204
- Sanofi-aventis U.S. LLC$184
- Amgen$175
- Amarin Pharma, Inc.$174
- Novartis$162
- plus $716 from 14 others
What the payments were for
- Food & beverage$1,871100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 14 | $262 |
| Novo Nordisk | 26 | $204 |
| Sanofi-aventis U.S. LLC | 12 | $184 |
| Amgen | 10 | $175 |
| Amarin Pharma, Inc. | 9 | $174 |
| Novartis | 9 | $162 |
| Merck | 12 | $138 |
| GSK | 7 | $124 |
| Gilead | 5 | $113 |
| AbbVie(2 entities) | 6 | $74 |
| Pfizer | 4 | $64 |
| Lilly USA, LLC | 2 | $34 |
| Boehringer Ingelheim | 1 | $26 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $26 |
| Hikma Pharmaceuticals USA | 2 | $26 |
| Astellas Pharma US Inc | 2 | $26 |
| Sanofi | 1 | $24 |
| Daiichi Sankyo Inc. | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $13 |
| Assertio Therapeutics, Inc. | 1 | $12 |
How this compares
$1,877 in reported general payments places this provider in the 80th percentile of 2,979 internal medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 161 | $169,563 |
| MounjaroTirzepatide | 90 | $94,988 |
| JardianceEmpagliflozin | 72 | $71,300 |
| XareltoRivaroxaban | 56 | $66,650 |
| OzempicSemaglutide | 33 | $40,243 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 20 | $28,890 |
| JanuviaSitagliptin Phosphate | 25 | $26,619 |
| TrulicityDulaglutide | 25 | $22,878 |
| EntrestoSacubitril/Valsartan | 27 | $21,816 |
| Tresiba Flextouch U-200Insulin Degludec | 12 | $21,310 |
| MyrbetriqMirabegron | 32 | $20,199 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 15 | $17,856 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 27 | $16,489 |
| Xigduo XrDapaglifloz Propaned/Metformin | 14 | $16,446 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $15,473 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $64 | $169,563161 claims |
| Lilly USA, LLCMounjaro, Trulicity | $34 | $117,866115 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $26 | $100,18992 claims |
| MerckJanuvia, Janumet Xr | $138 | $44,47540 claims |
| GSKAnoro Ellipta, Breo Ellipta, Incruse Ellipta | $124 | $41,27173 claims |
| Novo NordiskOzempic | $204 | $40,24333 claims |
| NovartisEntresto | $162 | $21,81627 claims |
| Astellas Pharma US IncMyrbetriq | $26 | $20,19932 claims |
| AstraZenecaSymbicort | $262 | $6,88416 claims |
| AbbVieSynthroid | $74 | $6,81179 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,979 internal medicine providers in Maryland.
Other internal medicine in Baltimore
- Kristen MarroneBaltimore$5.6M
- Peta-Gay Jackson BoothBaltimore$3.6M
- Mark YarchoanBaltimore$2.4M
- Gabrielle PrinceBaltimore$2.1M
- Jessica TaoBaltimore$1.2M
- Ana-Maria OrbaiBaltimore$1.1M
- Julie PaikBaltimore$1M
- Christopher MelaniBaltimore$997K
- Ethel WeldBaltimore$792K
- Christian GockeBaltimore$725K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.